Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Doxil and Doxorubicin in Cancer Patients
NCT03975205Phase 1Unknown
- Sponsor
- Sutphin Drugs
- Start
- Jul 2019
- Primary completion
- Oct 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of doxorubicin in lymphoma, leukemia and carcinoma (2 arms), sponsored by Sutphin Drugs. Primary endpoints: Bioavailability of Doxil versus Doxorubicin at 72 hours, Area Under the Curve at 72 hours and 1 more. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
lymphomaleukemiacarcinoma
Beyond the preview
Go deeper on NCT03975205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03975205.